drugset / Trial / NCT00800176

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

NCT00800176

Phase 2 Completed 394 enrolled Hoffmann-La Roche
RandomizedParallel-groupDouble-blindTreatment

Summary

This 6 arm study will evaluate the efficacy, safety and pharmacokinetics of 5 doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus. Patients will be randomized to one of 6 groups to receive RO4998452 at doses of 2.5mg, 5mg, 10mg, 20mg or 40mg po daily, or placebo daily. Patients pre-treated with stable metformin will continue to take their usual dose of metformin throughout the study.The anticipated time on study treatment is \<=3 months

Timeline

Start
2009-01-22
Primary completion
2009-10-28
Completion
2009-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject TOFOGLIFLOZIN ANHYDROUS Other / unclassified 2.5 mg Oral
Subject TOFOGLIFLOZIN ANHYDROUS Other / unclassified 5 mg Oral
Subject TOFOGLIFLOZIN ANHYDROUS Other / unclassified 10 mg Oral
Subject TOFOGLIFLOZIN ANHYDROUS Other / unclassified 20 mg Oral
Subject TOFOGLIFLOZIN ANHYDROUS Other / unclassified 40 mg Oral